ClinVar Miner

Submissions for variant NM_144563.3(RPIA):c.347-1G>A

dbSNP: rs1422698928
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001193230 SCV001361954 pathogenic Deficiency of ribose-5-phosphate isomerase 2019-03-19 criteria provided, single submitter clinical testing Variant summary: RPIA c.347-1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: five predicts the variant abolishes a 3' splicing acceptor site. The variant was absent in 246204 control chromosomes (gnomAD). c.347-1G>A has been reported in the literature in a compound heterozygous individual affected with Ribose 5-phosphate isomerase deficiency, who had significant elevations of ribitol and arabitol (>20x), consistent with this diagnosis (Brooks 2018). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.